Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants

RAS is the most frequently mutated oncogene in human cancer, yet limited treatments are available for patients with mutations beyond KRAS G12C. While pan-RAS inhibitors have entered the clinic to benefit a broader population of patients harboring RAS mutations, we sought to develop pan-KRAS inhibitors (selective for KRAS over HRAS and NRAS) that may offer an improved therapeutic index. Herein, we describe the discovery of GNE-6226, a pan-KRAS inhibitor exhibiting exquisite potency across a range of KRAS mutants. Using a structure-based design, we transitioned from mutant-selective inhibitors to a pan-KRAS inhibition profile, identifying the aminopyridine headgroup as a crucial motif. This headgroup establishes key ligand−protein interactions with conserved residues within the switch-II pocket while avoiding steric clashes with KRAS mutants. We present extensive cellular and in vivo profiling of GNE-6226, highlighting its robust MAPK pathway modulation and tumor growth inhibition in vivo across G12V- and G12D-mutant xenograft mouse models.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-21
DOI
https://doi.org/10.1021/acs.jmedchem.6c02035
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants

Stephanie Dale, Matthew L. Landry, Elizabeth H. Kelley, Luca Gerosa et al.
Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase Signaling
article

Discovery of Pan-KRAS Inhibitor GNE-6226: Harnessing an Aminopyridine Pharmacophore to Broadly Target KRAS Mutants

Stephanie Dale, Matthew L. Landry, Elizabeth H. Kelley, Luca Gerosa, Marie Evangelista, Jeremy M. Murray, Cheng Shao, Lionel Rougé, Pablo Saenz-Lopez Larrocha, Kamakoti P. Bhat, Maureen H. Beresini, Cecile C. de la Cruz, 孙银蕾, Darlene Dela Cruz, Jack A. Terrett, Jun Zou, Binqing Q. Wei, Lin Deng, Mark A. Merchant, Benjamin D. Ravetz, F. Esra Demircioglu, Thomas Hunsaker, Matthew J. Saabye, Sushant Malhotra, Jingwei Cai, Lewis J. Gazzard, Aijun Lu, Fang Ma, Ehud Segal, Stefan Chun, Xin Ye, Eva Lin, Yulai Zhang, Kaylee Lee, Guosheng Wu, Xiaodan Chang, Weiru Wang
article en

Abstract

RAS is the most frequently mutated oncogene in human cancer, yet limited treatments are available for patients with mutations beyond KRAS G12C. While pan-RAS inhibitors have entered the clinic to benefit a broader population of patients harboring RAS mutations, we sought to develop pan-KRAS inhibitors (selective for KRAS over HRAS and NRAS) that may offer an improved therapeutic index. Herein, we describe the discovery of GNE-6226, a pan-KRAS inhibitor exhibiting exquisite potency across a range of KRAS mutants. Using a structure-based design, we transitioned from mutant-selective inhibitors to a pan-KRAS inhibition profile, identifying the aminopyridine headgroup as a crucial motif. This headgroup establishes key ligand−protein interactions with conserved residues within the switch-II pocket while avoiding steric clashes with KRAS mutants. We present extensive cellular and in vivo profiling of GNE-6226, highlighting its robust MAPK pathway modulation and tumor growth inhibition in vivo across G12V- and G12D-mutant xenograft mouse models.

Journal of Medicinal Chemistry
Genentech (US), Confluence Life Sciences (United States) (US)
Protein Kinase Regulation and GTPase Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon